Entering text into the input field will update the search result below

CNC, VICL among premarket losers

Jun. 03, 2019 9:10 AM ETBy: Gaurav Batavia, SA News Editor
  • DelMar Pharmaceuticals (DMPI) -41% on equity offering.
  • Vascular Biogenics (VBLT) -13% as radiographic analysis of VB-111 Phase 2 and Phase 3 studies in recurrent GBM showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity.
  • Centene (CNC) -8%.
  • Ability (ABIL) -8%.
  • Eltek (ELTK) -7%.
  • Stellar Biotechnologies (SBOT) -5%.
  • Vical (VICL) -6% on merger with Brickell.

Recommended For You

More Trending News